Oral Rivaroxaban in Children With Venous Thrombosis

Venous Thrombosis Clinical Trial

— EINSTEINJunior  

Official title:

30-day, Single-arm Study of the Safety, Efficacy and the Pharmacokinetic and Pharmacodynamic Properties of Oral Rivaroxaban in Children With Various Manifestations of Venous Thrombosis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01684423
• Other study ID #: 14373
• Secondary ID: 2011-004539-30
• Status: Completed
• Phase: Phase 2
• First received: September 11, 2012
• Last updated: August 25, 2017
• Start date: February 19, 2013
• Est. completion date: September 1, 2016

Study information

• Verified date: August 2017
• Source: Bayer
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to find out whether rivaroxaban is safe to use in children and how long it stays in the body. There will also be a check for bleeding and worsening of blood clots.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 64
• Est. completion date: September 1, 2016
• Est. primary completion date: September 1, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 6 Years to 17 Years

Eligibility

Inclusion Criteria:

• Children aged 6 to < 18 years with documented symptomatic or asymptomatic venous thrombosis treated for at least 2 months or, in case of catheter related thrombosis, treated for at least 6 weeks with LMWH (low molecular weight heparin), , fondaparinux and/or VKA (vitamin K antagonist).

• Informed consent provided and, if applicable, child assent provided

Exclusion Criteria:

• Active bleeding or high risk for bleeding contraindicating anticoagulant therapy

• Symptomatic progression of venous thrombosis during preceding anticoagulant treatment

• Planned invasive procedures, including lumbar puncture and removal of non peripherally placed central lines during study treatment

• An estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m2

• Hepatic disease which is associated with coagulopathy leading to a clinically relevant bleeding risk or ALT > 5x upper level of normal (ULN) or total bilirubin > 2x ULN with direct bilirubin > 20% of the total

• Platelet count < 50 x 10^9/L

• Hypertension defined as > 95th age percentile

• Life expectancy < 3 months

• Concomitant use of strong inhibitors of both cytochrome P450 isoenzyme 3A4 (CYP3A4) and P-glycoprotein (P-gp), i.e. all human immunodeficiency virus protease inhibitors and the following azole antimycotics agents: ketoconazole, itraconazole, voriconazole, posaconazole, if used systemically

• Concomitant use of strong inducers of CYP3A4, i.e. rifampicin, rifabutin, phenobarbital, phenytoin and carbamazepine

Related Conditions & MeSH terms

• Thrombosis
• Venous Thrombosis

Intervention

Drug:
• Rivaroxaban (Xarelto, BAY59-7939)
Subjects were administered with age- and body weight-adjusted oral dose of rivaroxaban (BAY59-7939) IR tablet once daily under fed conditions for 30 days.
• Active comparator
Subjects received comparator as per standard of care. The dosage given was to be adjusted based on the individual body weight (low molecular weight heparin, fondaparinux) or international normalized ratio (INR) adjusted (vitamin K antagonist).
• Rivaroxaban (BAY59-7939) suspension
Subjects aged were administered with age- and body weight-adjusted oral dose of rivaroxaban (BAY59-7939) suspension under fed conditions twice daily.

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Bayer	Janssen Research & Development, LLC

Countries where clinical trial is conducted

United States,  Australia,  Austria,  Canada,  France,  Germany,  Israel,  Italy,  Netherlands,  Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Subjects With Major and Clinically Relevant Non-Major Bleeding Events	Central independent adjudication committee (CIAC) classified bleeding as follows: Major bleeding is defined as overt bleeding and: associated with a fall in hemoglobin of 2 gram/decilitre (g/dL) or more, or; leading to a transfusion of the equivalent of 2 or more units of packed red blood cells or whole blood in adults, or; occurring in a critical site, e.g. intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal, or; contributing to death.; Clinically relevant non-major bleeding is defined as overt bleeding not meeting the criteria for major bleeding, but associated with: medical intervention, or; unscheduled contact (visit or telephone call) with a physician, or; cessation (temporary) of study treatment, or; discomfort for the child such as pain or; impairment of activities of daily life (such as loss of school days or hospitalization).	From start of study drug administration until end of the 30-day treatment period
Secondary	Number of Subjects With Symptomatic Recurrent Venous Thromboembolism	The occurrence of recurrent venous thromboembolism was summarized by age group. Symptomatic recurrence of venous thrombosis was documented by the appropriate imaging test.	From start of study drug administration until end of the 30-day treatment period
Secondary	Number of Subjects With Asymptomatic Deterioration in Thrombotic Burden	The occurrence of asymptomatic deterioration in thrombotic burden was summarized by age group. Asymptomatic deterioration in thrombotic burden was documented by the appropriate imaging test and the results were classified as normalized, improved, no relevant change, deteriorated, not evaluable or not available.	Repeat imaging at the end of the 30 day treatment period
Secondary	Change From Baseline in Prothrombin Time at Specified Time Points	Prothrombin time is a global clotting test used for the assessment of the extrinsic pathway of the blood coagulation cascade.	0 hours (pre-dose) to 8 hours post-dose on Day 15 and 24 hours post-dose on Day 31
Secondary	Change From Baseline in Activated Partial Thromboplastin Time at Specified Time Points	The Activated partial thromboplastin time (aPTT) is a screening test for the intrinsic pathway.	0 hours (pre-dose) to 8 hours post-dose on Day 15 and 24 hours post-dose on Day 31
Secondary	Anti-factor Xa Values at Specified Time Points	The individual anti-Factor Xa activity was determined ex-vivo using a photometric method.	0 hours (pre-dose) to 8 hours post-dose on Day 15 and 24 hours post-dose on Day 31
Secondary	Concentration of Rivaroxaban in Plasma as a Measure of Pharmacokinetics at Specified Time Points	Geometric and percentage geometric coefficient of variation (%CV) were reported.	0 hours (pre-dose) to 8 hours post-dose on Day 15 and 24 hours post-dose on Day 31

External Links

•   Click here and search for drug information provided by the FDA.
•   Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.
•   Click here to find information about studies related to Bayer Healthcare products conducted in Europe
•   Click here to find results for studies related to Bayer Healthcare products.